TF and cancer: While (fl)TF is still being actively pursued clinically, we posit that asTF is the preferred TF form to target in PDAC and other solid tumors due to both a low risk of bleeding complications, as well as superior selectivity for cancer cells and tissues; further, hRabMab1 is not an ADC and is, thus, not likely to cause tissue toxicity.